News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Long-acting HIV treatment news

Show

From To
Long-acting HIV treatment
ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice

The long-acting injectable regimen has been granted Priority Review status by the FDA, with a target approval date set for December 29, 2019

Published
11 July 2019
From
ViiV Healthcare press release
Long-acting HIV treatment
Lyndra Therapeutics and Gilead Sciences to Collaborate on Development of Ultra-Long-Acting HIV Therapeutics

Lyndra Therapeutics, the company making daily pills a thing of the past, has announced a partnership with Gilead Sciences, Inc. to develop and commercialize ultra-long-acting oral HIV therapies. Gilead will have exclusive rights to Lyndra’s therapeutics platform for ultra-long-acting formulations related to HIV.

Published
10 July 2019
From
Lyndra Therapeutics press release
Long-acting HIV treatment
Study Finds Long-Acting HIV Meds Are Acceptable to Many People, but Differences Exist Among Groups

Now that long-acting antiretroviral therapy (LA-ART) is nearly a reality, is it something that people with HIV will prefer over once-daily pills? A study presented during a poster session at the International Conference on HIV Treatment and Prevention Adherence tried to find out whether LA-ART was as acceptable as daily-pill ART among 374 people living with HIV in a clinic in Houston. While they found that overall, LA-ART was acceptable among a majority of people, it wasn't equally acceptable among all groups.

Published
25 June 2019
From
The Body Pro
Long-acting HIV treatment
NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens

A clinical trial to evaluate long-acting antiretroviral therapy (ART) for maintaining HIV suppression in people for whom adhering to conventional daily oral ART has been a challenge has begun at research sites across the United States. The study, called Long-Acting Therapy to Improve Treatment Success in Daily Life, or LATITUDE, will help determine whether a combination of two experimental injectable formulations of ART are superior to conventional oral ART in managing HIV infection in this population.

Published
09 May 2019
From
National Institute of Allergy and Infectious Diseases
Long-acting HIV treatment
ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine

If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV

Published
29 April 2019
From
ViiV press release
Long-acting HIV treatment
Long-Acting HIV Treatment Is Coming. Our Health Care System Needs to Prepare

New conversations are starting in HIV care as phase III trials have shown that monthly injections of cabotegravir and rilpivirine (Edurant) are non-inferior to a three-drug pill regimen. In 2018, TheBody asked a range of people living with HIV about their willingness to switch to an injectible, and most had mixed feelings. But even if there's widespread interest in this new way of taking antiretroviral therapy (and most likely also prevention, not too far away), it's important to consider not just the willingness of people to move to this new form of treatment, but whether health care systems and providers in the U.S. are ready to support this innovation.

Published
16 April 2019
From
The Body Pro
Long-acting HIV treatment
Jose Arribas, MD, on the Challenges That Come With Long-Acting Injectables

The announcement of the results of the FLAIR and ATLAS studies at the Annual Conference on Retroviruses and Opportunistic Infections in March was a major step forward in the field of long-acting injectables for the treatment and management of HIV. But with advances come challenges.

Published
15 April 2019
From
Contagion Live
Treatment simplification strategies
Laura Waters, MD, FRCP: Can Two Drugs Tango?

In a symposium presentation at the Annual Conference on Retroviruses and Opportunistic Infections (CROI 2019), Laura Waters, MD, FRCP, discussed the developments of 2-drug regimens for HIV treatments, as well as the questions that remain unanswered. Contagion® sat down with Dr. Waters for an exclusive interview about her presentation and to discuss new data from several studies presented at the meeting.

Published
12 March 2019
From
Contagion Live
New and experimental HIV treatments
HIV capsid inhibitor may offer long-term viral suppression

An experimental HIV capsid inhibitor appears safe and may be able to be administered once every three months or less, according to results from an early clinical

Published
11 March 2019
By
Liz Highleyman
Long-acting HIV treatment
Long-acting injectable treatment maintains viral suppression

A combination of two long-acting injectable anti-HIV drugs taken once monthly had a very low rate of treatment failure and a favourable safety profile, according to results

Published
08 March 2019
By
Liz Highleyman
← First12345...7Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.